Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes

BACKGROUND: Olaparib (Lynparza™) is a PARP inhibitor approved for advanced BRCA-mutated (BRCAm) ovarian cancer. PARP inhibitors may benefit patients whose tumours are dysfunctional in DNA repair mechanisms unrelated to BRCA1/2. We report exploratory analyses, including the long-term outcome of candi...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Br J Cancer
Main Authors: Hodgson, Darren R., Dougherty, Brian A., Lai, Zhongwu, Fielding, Anitra, Grinsted, Lynda, Spencer, Stuart, O’Connor, Mark J., Ho, Tony W., Robertson, Jane D., Lanchbury, Jerry S., Timms, Kirsten M., Gutin, Alexander, Orr, Maria, Jones, Helen, Gilks, Blake, Womack, Chris, Gourley, Charlie, Ledermann, Jonathan, Barrett, J. Carl
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group UK 2018
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6265286/
https://ncbi.nlm.nih.gov/pubmed/30353044
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-018-0274-8
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki